Title

Long-Term Safety Results from a Phase 3 Open-Label Study of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis.

Document Type

Article

Publication Date

1-1-2019

Publication Title

J Am Acad Dermatol

PubMed ID

30227193

Volume

80

Issue

1

First Page

282

Last Page

285

Share

COinS